350 related articles for article (PubMed ID: 18381946)
1. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
Brostjan C; Gebhardt K; Gruenberger B; Steinrueck V; Zommer H; Freudenthaler H; Roka S; Gruenberger T
Clin Cancer Res; 2008 Apr; 14(7):2065-74. PubMed ID: 18381946
[TBL] [Abstract][Full Text] [Related]
2. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
Scappaticci FA; Fehrenbacher L; Cartwright T; Hainsworth JD; Heim W; Berlin J; Kabbinavar F; Novotny W; Sarkar S; Hurwitz H
J Surg Oncol; 2005 Sep; 91(3):173-80. PubMed ID: 16118771
[TBL] [Abstract][Full Text] [Related]
3. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer.
Tas F; Duranyildiz D; Soydinc HO; Cicin I; Selam M; Uygun K; Disci R; Yasasever V; Topuz E
Cancer Chemother Pharmacol; 2008 Apr; 61(5):721-5. PubMed ID: 17554539
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
5. [Anti-angiogenic treatment and colorectal cancer].
André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
[TBL] [Abstract][Full Text] [Related]
6. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.
D'Angelica M; Kornprat P; Gonen M; Chung KY; Jarnagin WR; DeMatteo RP; Fong Y; Kemeny N; Blumgart LH; Saltz LB
Ann Surg Oncol; 2007 Feb; 14(2):759-65. PubMed ID: 17103075
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer.
Thornton AD; Ravn P; Winslet M; Chester K
Br J Surg; 2006 Dec; 93(12):1456-63. PubMed ID: 17115389
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.
Krämer I; Lipp HP
J Clin Pharm Ther; 2007 Feb; 32(1):1-14. PubMed ID: 17286784
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
Del Vecchio M; Mortarini R; Canova S; Di Guardo L; Pimpinelli N; Sertoli MR; Bedognetti D; Queirolo P; Morosini P; Perrone T; Bajetta E; Anichini A
Clin Cancer Res; 2010 Dec; 16(23):5862-72. PubMed ID: 21030496
[TBL] [Abstract][Full Text] [Related]
10. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
[TBL] [Abstract][Full Text] [Related]
11. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study.
Tamandl D; Gruenberger B; Klinger M; Herberger B; Kaczirek K; Fleischmann E; Gruenberger T
Ann Surg; 2010 Jul; 252(1):124-30. PubMed ID: 20562613
[TBL] [Abstract][Full Text] [Related]
12. Implications of bevacizumab on vascular endothelial growth factor and endostatin in human choroidal neovascularisation.
Tatar O; Shinoda K; Kaiserling E; Claes C; Eckardt C; Eckert T; Pertile G; Boeyden V; Scharioth GB; Yoeruek E; Szurman P; Bartz-Schmidt KU; ; Grisanti S
Br J Ophthalmol; 2009 Feb; 93(2):159-65. PubMed ID: 18838410
[TBL] [Abstract][Full Text] [Related]
13. Antivascular endothelial growth factor monoclonal antibody therapy: a promising paradigm in colorectal cancer.
Franson PJ; Lapka DV
Clin J Oncol Nurs; 2005 Feb; 9(1):55-60. PubMed ID: 15751499
[TBL] [Abstract][Full Text] [Related]
14. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
Karp JE; Gojo I; Pili R; Gocke CD; Greer J; Guo C; Qian D; Morris L; Tidwell M; Chen H; Zwiebel J
Clin Cancer Res; 2004 Jun; 10(11):3577-85. PubMed ID: 15173063
[TBL] [Abstract][Full Text] [Related]
15. Managing patients with metastatic colorectal cancer on bevacizumab.
Lemmens L; Claes V; Uzzell M
Br J Nurs; 2008 Aug 14-Sep 10; 17(15):944-9. PubMed ID: 18983014
[TBL] [Abstract][Full Text] [Related]
16. The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection.
Cheon EC; Small W; Strouch MJ; Krantz SB; Rademaker A; Mulcahy MF; Benson AB; Bentrem DJ; Talamonti MS
J Surg Oncol; 2010 Oct; 102(5):539-42. PubMed ID: 20812264
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma.
Tanaka K; Sonoo H; Kurebayashi J; Nomura T; Ohkubo S; Yamamoto Y; Yamamoto S
Clin Cancer Res; 2002 May; 8(5):1125-31. PubMed ID: 12006528
[TBL] [Abstract][Full Text] [Related]
18. Influence of non-toxic doses of bevacizumab and ranibizumab on endothelial functions and inhibition of angiogenesis.
Barzelay A; Lowenstein A; George J; Barak A
Curr Eye Res; 2010 Sep; 35(9):835-41. PubMed ID: 20795866
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab in the treatment of metastatic colorectal cancer.
Caprioni F; Fornarini G
Future Oncol; 2007 Apr; 3(2):141-8. PubMed ID: 17381413
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic and angiogenic growth factors accumulate during routine storage of apheresis platelet concentrates.
Kanter J; Khan SY; Kelher M; Gore L; Silliman CC
Clin Cancer Res; 2008 Jun; 14(12):3942-7. PubMed ID: 18559616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
